Home » FDA to Review Hemispherx Drug in December
FDA to Review Hemispherx Drug in December
Shares of Hemispherx Biopharma fell after the drugmaker said that the FDA has scheduled a meeting for December to review its experimental drug for chronic fatigue syndrome.
Businessweek
Businessweek
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May